Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TYME

Tyme Technologies (TYME) Stock Price, News & Analysis

Tyme Technologies logo

About Tyme Technologies Stock (NASDAQ:TYME)

Key Stats

Today's Range
$0.29
$0.32
50-Day Range
$0.24
$0.35
52-Week Range
$0.22
$1.14
Volume
2.68 million shs
Average Volume
1.01 million shs
Market Capitalization
$53.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

TYME Stock News Headlines

2025: Digital Asset Insights You Need to Know
Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.
Creating a Winter Herb Garden Indoors
See More Headlines

TYME Stock Analysis - Frequently Asked Questions

Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyme Technologies investors own include NIO (NIO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Tonix Pharmaceuticals (TNXP), SCYNEXIS (SCYX) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
11/08/2021
Today
11/23/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYME
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-23,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
143,104,000
Market Cap
$53.50 million
Optionable
Optionable
Beta
0.93
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:TYME) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners